ASTX660 是一种口服生物可利用的 cIAP 和 XIAP 双重拮抗剂。

ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP.

Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660.

ASTX660 (daily oral treatment) inhibits tumor growth moderately but not a regression in HCC1806 xenografts in mice.

1799328-86-1

C30H42FN5O3

539.68

DMSO:47 mg/mL(87.09 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years